Linked Life Data

19738118

Source:http://linkedlifedata.com/resource/pubmed/id/19738118

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19738118rdf:typepubmed:Citationlld:pubmed
pubmed-article:19738118lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:19738118lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:19738118lifeskim:mentionsumls-concept:C0278791lld:lifeskim
pubmed-article:19738118lifeskim:mentionsumls-concept:C0010583lld:lifeskim
pubmed-article:19738118lifeskim:mentionsumls-concept:C0038952lld:lifeskim
pubmed-article:19738118lifeskim:mentionsumls-concept:C0059985lld:lifeskim
pubmed-article:19738118lifeskim:mentionsumls-concept:C0914297lld:lifeskim
pubmed-article:19738118lifeskim:mentionsumls-concept:C0282461lld:lifeskim
pubmed-article:19738118pubmed:issue31lld:pubmed
pubmed-article:19738118pubmed:dateCreated2009-10-30lld:pubmed
pubmed-article:19738118pubmed:abstractTextA randomized trial of oblimersen plus fludarabine/cyclophosphamide (OBL-FC; n = 120) versus FC (n = 121) was conducted in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). The primary end point was met: the complete response (CR) rate, defined as complete or nodular partial response, was significantly greater with OBL-FC than with FC (17% v 7%; P = .025). Among patients with CR, response duration was significantly longer with OBL-FC than with FC (median not reached; > 36 months v 22 months; P = .03). Maximum benefit with OBL-FC, including a four-fold increase in CR rate and a survival benefit with 3 years of follow-up (hazard ratio, 0.53; P = .05), was observed in patients with fludarabine-sensitive disease. We evaluated long-term survival and poststudy CLL therapy among all randomly assigned patients.lld:pubmed
pubmed-article:19738118pubmed:languageenglld:pubmed
pubmed-article:19738118pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19738118pubmed:citationSubsetIMlld:pubmed
pubmed-article:19738118pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19738118pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19738118pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19738118pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19738118pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19738118pubmed:statusMEDLINElld:pubmed
pubmed-article:19738118pubmed:monthNovlld:pubmed
pubmed-article:19738118pubmed:issn1527-7755lld:pubmed
pubmed-article:19738118pubmed:authorpubmed-author:ItriLoretta...lld:pubmed
pubmed-article:19738118pubmed:authorpubmed-author:MooreJoseph...lld:pubmed
pubmed-article:19738118pubmed:authorpubmed-author:O'BrienSusanSlld:pubmed
pubmed-article:19738118pubmed:authorpubmed-author:SeymourJohn...lld:pubmed
pubmed-article:19738118pubmed:authorpubmed-author:RaiKanti RKRlld:pubmed
pubmed-article:19738118pubmed:authorpubmed-author:SkotnickiAlek...lld:pubmed
pubmed-article:19738118pubmed:authorpubmed-author:BoydThomas...lld:pubmed
pubmed-article:19738118pubmed:authorpubmed-author:LarrattLoree...lld:pubmed
pubmed-article:19738118pubmed:authorpubmed-author:GribbenJohnJlld:pubmed
pubmed-article:19738118pubmed:authorpubmed-author:Chanan-KhanAs...lld:pubmed
pubmed-article:19738118pubmed:authorpubmed-author:KozinerBenjam...lld:pubmed
pubmed-article:19738118pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19738118pubmed:day1lld:pubmed
pubmed-article:19738118pubmed:volume27lld:pubmed
pubmed-article:19738118pubmed:ownerNLMlld:pubmed
pubmed-article:19738118pubmed:authorsCompleteYlld:pubmed
pubmed-article:19738118pubmed:pagination5208-12lld:pubmed
pubmed-article:19738118pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:19738118pubmed:meshHeadingpubmed-meshheading:19738118...lld:pubmed
pubmed-article:19738118pubmed:meshHeadingpubmed-meshheading:19738118...lld:pubmed
pubmed-article:19738118pubmed:meshHeadingpubmed-meshheading:19738118...lld:pubmed
pubmed-article:19738118pubmed:meshHeadingpubmed-meshheading:19738118...lld:pubmed
pubmed-article:19738118pubmed:meshHeadingpubmed-meshheading:19738118...lld:pubmed
pubmed-article:19738118pubmed:meshHeadingpubmed-meshheading:19738118...lld:pubmed
pubmed-article:19738118pubmed:meshHeadingpubmed-meshheading:19738118...lld:pubmed
pubmed-article:19738118pubmed:meshHeadingpubmed-meshheading:19738118...lld:pubmed
pubmed-article:19738118pubmed:meshHeadingpubmed-meshheading:19738118...lld:pubmed
pubmed-article:19738118pubmed:meshHeadingpubmed-meshheading:19738118...lld:pubmed
pubmed-article:19738118pubmed:meshHeadingpubmed-meshheading:19738118...lld:pubmed
pubmed-article:19738118pubmed:meshHeadingpubmed-meshheading:19738118...lld:pubmed
pubmed-article:19738118pubmed:meshHeadingpubmed-meshheading:19738118...lld:pubmed
pubmed-article:19738118pubmed:meshHeadingpubmed-meshheading:19738118...lld:pubmed
pubmed-article:19738118pubmed:year2009lld:pubmed
pubmed-article:19738118pubmed:articleTitle5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.lld:pubmed
pubmed-article:19738118pubmed:affiliationDivision of Hematology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. sobrien@mdanderson.orglld:pubmed
pubmed-article:19738118pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19738118pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:19738118pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:19738118pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:19738118pubmed:publicationTypeClinical Trial, Phase IIIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19738118lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19738118lld:pubmed